Jagsonpal Pharmaceuticals cash flow

Latest FY26

Cash from operations: ₹46.8cr−15.3% on FY25
Capital spending: ₹0.0cr−100.0% on FY25
Free cash flow: ₹46.8cr−14.8% on FY25
Cash from financing: −₹12.1cr−₹11.7 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	9.4	8.1	1.7	1.2
	—	−1.0	−1.0	−0.8	−0.4
	—	11.7	7.6	8.6	3.4
	—	0.0	0.0	0.0	0.4
	—	2.8	6.8	13.3	−11.5
	—	−15.5	−18.5	5.4	−0.6
	—	0.5	0.0	5.3	9.1
	—	−4.0	−2.2	9.2	−5.6
	—	0.1	0.0	−0.1	1.9
	—	0.8	−0.8	3.5	−8.2
	—	1.8	2.1	−9.0	−2.0
	—	0.2	4.5	3.2	2.4
	—	−0.1	0.4	0.2	−0.3
Cash from operating activities
	60.8	57.5	69.9	29.9	34.8
	—	1.2	−6.4	13.8	12.6
	—	58.7	63.4	43.7	47.4
	—	11.9	8.1	8.5	7.3
	—	46.8	55.3	35.2	40.1
Cash from investing activities
	—	0.0	0.3	0.2	0.3
	—	−0.1	35.7	0.0	0.0
	—	−45.6	−88.4	−31.7	−54.3
	—	10.1	7.8	7.4	3.4
	—	0.0	0.0	0.0	0.1
	—	0.0	0.0	0.0	−0.3
	—	−35.6	−45.1	−24.5	−51.6
Cash from financing activities
	—	0.1	0.1	0.0	0.0
	—	−12.1	−11.6	−8.9	0.0
	—	−12.1	−11.7	−8.9	0.0
	—	−1.0	−1.5	1.7	−11.5
	—	−1.0	−1.5	1.7	−11.5
	—	—	—	12.8	11.1
Reference items
	61.4	58.1	51.1	23.1	34.2
	20.4%	20.2%	19.0%	11.1%	14.4%
	46.8	46.8	55.0	34.9	39.8
	—	46.7	54.9	34.9	—
	₹6.99	₹6.99	₹8.21	₹5.21	₹5.95
	33.04×	—	—	—	—
	—	1.09×	1.00×	1.57×	1.50×
	—	11.9	8.1	8.5	7.3
	—	0.1	0.1	0.0	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

JAGSNPHARM₹230.96

Jagsonpal Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersAMRUTANJAN NGLFINE SYNCOMF HESTERBIO SIGACHI LINCOLN WINDLASMcap ₹1,547 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	1.2	1.7	8.1	9.4	—
+ Finance Costs	-0.4	-0.8	-1.0	-1.0	—
+ Interest Income	3.4	8.6	7.6	11.7	—
+ Fair Value (Gains) / Losses	0.4	0.0	0.0	0.0	—
+ Undistributed Profits of Associates	-11.5	13.3	6.8	2.8	—
+ Other Reconciling Items	-0.6	5.4	-18.5	-15.5	—
Changes in Working Capital
+ Inventories	9.1	5.3	0.0	0.5	—
+ Trade Receivables — Current	-5.6	9.2	-2.2	-4.0	—
+ Other Financial Assets — Current	1.9	-0.1	0.0	0.1	—
+ Other Current Assets	-8.2	3.5	-0.8	0.8	—
+ Trade Payables — Current	-2.0	-9.0	2.1	1.8	—
+ Other Financial Liabilities — Current	2.4	3.2	4.5	0.2	—
+ Provisions — Current	-0.3	0.2	0.4	-0.1	—
Cash from Operating Activities
Profit Before Tax (per I/S)	34.8	29.9	69.9	57.5	60.8
+ Total Adjustments (incl. Working Capital)	12.6	13.8	-6.4	1.2	—
Cash from Operations (pre-tax)	47.4	43.7	63.4	58.7	—
+ Income Taxes Paid	7.3	8.5	8.1	11.9	—
Cash from Operating Activities	40.1	35.2	55.3	46.8	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	0.3	0.2	0.3	0.0	—
+ Disp of Fixed Assets	0.0	0.0	35.7	-0.1	—
+ Disp of Intangible Assets	-54.3	-31.7	-88.4	-45.6	—
+ Interest Received — Investing	3.4	7.4	7.8	10.1	—
+ Income Taxes (Paid) / Refund — Investing	0.1	0.0	0.0	0.0	—
+ Other Inflows / (Outflows) — Investing	-0.3	0.0	0.0	0.0	—
Cash from Investing Activities	-51.6	-24.5	-45.1	-35.6	—
Cash from Financing Activities
+ Interest Paid	0.0	0.0	0.1	0.1	—
+ Other Inflows / (Outflows) — Financing	0.0	-8.9	-11.6	-12.1	—
Cash from Financing Activities	0.0	-8.9	-11.7	-12.1	—
Net Changes in Cash (pre-FX)	-11.5	1.7	-1.5	-1.0	—
Net Changes in Cash	-11.5	1.7	-1.5	-1.0	—
Closing Cash	11.1	12.8	—	—	—
Reference Items
EBITDA	34.2	23.1	51.1	58.1	61.4
EBITDA Margin %	14.43	11.05	19.01	20.22	20.43
Free Cash Flow (CFO − Capex)	39.8	34.9	55.0	46.8	46.8
Free Cash Flow to Equity	—	34.9	54.9	46.7	—
Free Cash Flow per Basic Share	5.95	5.21	8.21	6.99	6.99
Price to Free Cash Flow	—	—	—	—	33.04
Cash Flow to Net Income	1.50	1.57	1.00	1.09	—
Cash Paid for Taxes	7.3	8.5	8.1	11.9	—
Cash Paid for Interest	—	0.0	0.1	0.1	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.